Newsletter | May 8, 2025

05.08.25 -- What CDMOs Wish Biotechs Knew Before Submitting An RFP

SPONSOR

Did you know Catalent offers contracted analytical services?

With over 30+ years of experience, Catalent offers a comprehensive suite of orthogonal GMP analytical services for all biological modalities, from discovery to commercial phases. Our seasoned experts ensure exceptional on-time delivery and client satisfaction by providing tailored solutions to meet your unique needs—no matter the complexity, scale, or timeline. Watch our intro video to learn more about our capabilities!

FOCUS ON OUTSOURCING

What CDMOs Wish Biotechs Knew Before Submitting An RFP

This author has worked with CDMOs across different programs and therapeutic modalities. Each experience reinforced the same lesson: a strong RFP can make or break a partnership.

How-To Master Tech Transfer: Strategies To Sidestep Common Pitfalls

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

The Changing Vaccine Development Landscape

Review the different technologies that are being used to develop next-generation vaccines and the challenges and opportunities that these technologies present.

Advancements In Microbial Manufacturing Of Biopharmaceuticals

Dive into the evolution and future potential of microbial manufacturing in the biopharmaceutical industry to discover how digital tools can revolutionize development and production processes.

mRNA/saRNA Manufacturing RNA Analytics And Testing

Venkata Indurthi, Ph.D., shares insights into manufacturing RNA, including key downstream considerations for RNA characterization and how optimization can result in more efficient dosing.

The Right Partnerships Are Key To Streamlined Drug Development

Explore how to select the right CDMO partner for your pharmaceutical project to navigate the evolving drug development landscape and ensure successful outcomes.

Advancing Immune Cell Therapies And Overcoming Cost Challenges

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Scalable Suspension LVV Production Platforms

Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

SPONSOR

Multispecific molecules bring added complexity to downstream purification—think incorrect chain pairings, aggregation, fragmentation, and lower yields. Join Bioprocess Online Live as we explore how developers are addressing these challenges to achieve high purity and efficient processes. Gain insights into key considerations for downstream teams when designing purification strategies for these advanced biologics. Registration is free thanks to the support of Thermo Fisher Scientific.

OUTSOURCING SOLUTIONS

Technology Platforms For Diverse Allogeneic CGT Products - Mycenax

Capacity Update January 2025: Large Molecule Development - Catalent

Highly Potent And Complex API Contract Manufacturing - MilliporeSigma

Connect With Bioprocess Online: